A new generation of ready-to-use CAR-T therapy with improved activity and durability receives FDA orphan drug designation

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T-cell (AlloCAR T) products targeting cancer

Allogene's TurboCAR platform specifically activates signaling of specific cytokines in CAR-T cells

▲Introduction to ALLO-605 (Image source: Allogene's official website)

Preclinical results from ALLO-605, presented at the American Society of Hematology (ASH) annual meeting in December 2020, show that TurboCAR technology may improve cell therapy colonization and persistence and delay T cell exhaustion

Rafael Amado, MD, executive vice president of research and development and chief medical officer at Allogene, said: "Orphan drug designation marks an important step toward developing an anti-BCMA portfolio for patients with multiple myeloma and providing patients with an allogeneic CAR-T product.

References:

Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR T Cell Product Candidate, for the Treatment of Multiple Myeloma.